Details for New Drug Application (NDA): 216961
✉ Email this page to a colleague
The generic ingredient in THEOPHYLLINE is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
Summary for 216961
Tradename: | THEOPHYLLINE |
Applicant: | Teva Pharms Inc |
Ingredient: | theophylline |
Patents: | 0 |
Suppliers and Packaging for NDA: 216961
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3309 | 0480-3309-01 | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0480-3309-01) |
THEOPHYLLINE | theophylline | TABLET, EXTENDED RELEASE;ORAL | 216961 | ANDA | Teva Pharmaceuticals, Inc. | 0480-3310 | 0480-3310-01 | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0480-3310-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 300MG | ||||
Approval Date: | Oct 12, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 450MG | ||||
Approval Date: | Oct 12, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription